Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Zanubrutinib
Related studies linked through entity extraction aliases.
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2